Protagonist Therapeutics (NASDAQ:PTGX) announced today that the U.S. Food and Drug Administration (FDA) has approved ICOTYDE (icotrokinra) for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients aged 12 and older weighing at least 40 kg.
The approval marks a major clinical victory for the company’s oral peptide technology and significantly strengthens its financial position.
The regulatory green light was supported by data from four comprehensive Phase 3 clinical studies involving approximately 2,500 patients.
The trials demonstrated that ICOTYDE achieved high levels of skin clearance with a safety profile that compared favorably to existing injectable therapies.
Under a long-standing development and license agreement, Johnson & Johnson (NYSE:JNJ) will lead the global commercialization of the drug, integrating it into its market-leading immunology portfolio.
The approval immediately triggers a $50 million milestone payment from Johnson & Johnson to Protagonist.
Beyond the initial windfall, Protagonist remains eligible for up to $580 million in additional development and sales-based milestones.
Furthermore, the company will receive tiered royalties ranging from 6% to 10% on net global sales, providing a consistent, long-term revenue stream that management expects will fund its internal pipeline of next-generation oral therapeutics.